SCHEMBL6156433

SCHEMBL6156433

Cc1cc(NC(=O)N(Nc2cccc(C(=N)NO)c2)c2ccccc2)ccc1N1CCCCC1=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F10 P00742 2/20 0.43
SMN1; SMN2 Q16637 5/20 0.39
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
TSHR P16473 2/20 0.39
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
GAA P10253 2/20 0.37
GFER P55789 2/20 0.37
ALDH1A1 P00352 5/20 0.36
POLB P06746 2/20 0.36
KDM4E B2RXH2 1/20 0.36
HPGD P15428 1/20 0.36
MAPT P10636 2/20 0.35
LMNA P02545 3/20 0.34
TP53 P04637 2/20 0.34
ATM Q13315 1/20 0.34
MAPK1 P28482 1/20 0.34
GLA P06280 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6158838 0.92 F10 (0.53) F10SMN1; SMN2MEN1KMT2ATSHR
SCHEMBL6157569 0.84 TP53 (0.38) F10SMN1; SMN2MEN1KMT2ATSHR
SCHEMBL6156353 0.84 TP53 (0.40) SMN1; SMN2MEN1KMT2AGAAALDH1A1
SCHEMBL6156891 0.83 F10 (0.39) F10SMN1; SMN2MEN1KMT2ATSHR
SCHEMBL6156664 0.82 TP53 (0.40) F10SMN1; SMN2MEN1KMT2ATSHR
SCHEMBL5164191 0.80 F10 (0.51) F10SMN1; SMN2MEN1KMT2ATSHR
SCHEMBL6157482 0.79 F10 (0.68) F10SMN1; SMN2MEN1KMT2ATSHR
SCHEMBL6159517 0.77 F10 (0.37) F10SMN1; SMN2TSHRNPC1RAB9A
SCHEMBL5164836 0.77 F10 (0.46) F10KMT2ATSHRGAALMNA
SCHEMBL5164661 0.76 F10 (0.43) F10SMN1; SMN2MEN1KMT2ATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1501814-A1 SEMICARBAZIDE DERIVATIVES FOR COMBATING THROMBOEMBOLIC DISEASES MERCK PATENT GmbH (DE) 2005-02-02 EP claimed
WO-2003093254-A1 SEMICARBAZIDE DERIVATIVES FOR COMBATING THROMBOEMBOLIC DISEASES MERCK PATENT GMBH (DE) 2003-11-13 WO claimed
US-20050171102-A1 Semicarbazide derivatives for combating thromboembolic diseases MERCK PATENT GMBH (DE) 2005-08-04 US disclosed
EP-1501814-A1 SEMICARBAZIDE DERIVATIVES FOR COMBATING THROMBOEMBOLIC DISEASES MERCK PATENT GmbH (DE) 2005-02-02 EP disclosed
WO-2003093254-A1 SEMICARBAZIDE DERIVATIVES FOR COMBATING THROMBOEMBOLIC DISEASES MERCK PATENT GMBH (DE) 2003-11-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050171102-A1 Semicarbazide derivatives for combating thromboembolic diseases SERPINC1, F11, F12 F10 6/4885SMN1; SMN2 3250/4885MEN1 201/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.